Candriam SCA’s Ultragenyx Pharmaceutical RARE Stock Holding History

Candriam SCA’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23M	Buy	1,096,182 +296,798	+37%	+$6.68M	0.12%	176
2025 Q4	$18.4M	Buy	799,384 +44,670	+6%	+$1.47M	0.09%	199
2025 Q3	$22.7M	Buy	754,714 +228,447	+43%	+$6.85M	0.12%	165
2025 Q2	$19.1M	Sell	526,267 -201,750	-28%	-$7.27M	0.11%	173
2025 Q1	$26.4M	Buy	728,017 +53,760	+8%	+$2.24M	0.17%	129
2024 Q4	$28.4M	Sell	674,257 -38,835	-5%	-$1.93M	0.16%	126
2024 Q3	$39.6M	Buy	713,092 +24,150	+4%	+$1.23M	0.23%	100
2024 Q2	$28.3M	Buy	688,942 +171,345	+33%	+$7.32M	0.17%	126
2024 Q1	$24.2M	Buy	517,597 +369,117	+249%	+$17.4M	0.15%	142
2023 Q4	$7.1M	Buy	148,480 +99,000	+200%	+$3.84M	0.05%	299
2023 Q3	$1.76M	Hold	49,480	–	–	0.01%	466
2023 Q2	$2.28M	Sell	49,480 -11,155	-18%	-$517K	0.02%	474
2023 Q1	$2.24M	Buy	60,635 +11,155	+23%	+$479K	0.02%	557
2022 Q4	$2.29M	Hold	49,480	–	–	0.02%	554
2022 Q3	$2.05M	Hold	49,480	–	–	0.01%	579
2022 Q2	$2.95M	Hold	49,480	–	–	0.02%	418
2022 Q1	$3.59M	Hold	49,480	–	–	0.02%	414
2021 Q4	$4.16M	Hold	49,480	–	–	0.03%	391
2021 Q3	$4.46M	Hold	49,480	–	–	0.03%	420
2021 Q2	$4.72M	Sell	49,480 -48,949	-50%	-$5.1M	0.03%	417
2021 Q1	$13.1M	Hold	98,429	–	–	0.11%	211
2020 Q4	$13.6M	Buy	+98,429	New	+$11.7M	0.11%	214
2020 Q2	–	Sell	-121,500	Closed	-$5.07M	–	855
2020 Q1	$5.07M	Hold	121,500	–	–	0.06%	342
2019 Q4	$5.19M	Sell	121,500 -19,000	-14%	-$784K	0.06%	349
2019 Q3	$6.01M	Buy	140,500 +15,000	+12%	+$815K	0.08%	278
2019 Q2	$7.93M	Buy	125,500 +10,000	+9%	+$636K	0.1%	229
2019 Q1	$8.01M	Hold	115,500	–	–	0.1%	234
2018 Q4	$5.02M	Buy	115,500 +2,400	+2%	+$131K	0.08%	282
2018 Q3	$8.63M	Buy	113,100 +28,100	+33%	+$2.29M	0.11%	212
2018 Q2	$6.53M	Sell	85,000 -6,000	-7%	-$388K	0.1%	250
2018 Q1	$4.64M	Buy	91,000 +17,000	+23%	+$856K	0.08%	293
2017 Q4	$3.43M	Buy	74,000 +14,000	+23%	+$686K	0.06%	342
2017 Q3	$3.2M	Hold	60,000	–	–	0.06%	364
2017 Q2	$3.73M	Sell	60,000 -9,000	-13%	-$542K	0.07%	330
2017 Q1	$4.68M	Sell	69,000 -8,000	-10%	-$610K	0.09%	266
2016 Q4	$5.41M	Buy	77,000 +27,000	+54%	+$1.92M	0.12%	196
2016 Q3	$3.55M	Sell	50,000 -10,000	-17%	-$638K	0.09%	251
2016 Q2	$2.94M	Sell	60,000 -4,000	-6%	-$259K	0.08%	254
2016 Q1	$4.03M	Buy	64,000 +33,720	+111%	+$2.21M	0.1%	223
2015 Q4	$3.4M	Buy	30,280 +4,000	+15%	+$400K	0.09%	235
2015 Q3	$2.53M	Sell	26,280 -9,720	-27%	-$1.11M	0.06%	305
2015 Q2	$3.69M	Sell	36,000 -24,000	-40%	-$1.86M	0.08%	279
2015 Q1	$3.73M	Buy	+60,000	New	+$3.33M	0.08%	303

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Candriam SCA's RARE Position: Q1 2026 in Review

Candriam SCA increased its Ultragenyx Pharmaceutical (RARE) stake by 37% in Q1 2026, buying an estimated $6.68M and bringing the position to 1,096,182 shares worth $23M. The position accounts for 0.12% of the portfolio, ranked #176.

Candriam SCA first reported a position in RARE in Q1 2015 and has held it in 43 quarters since. The position peaked at $39.6M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Candriam SCA held 1,096,182 shares of Ultragenyx Pharmaceutical worth $23M as of Q1 2026.
Candriam SCA bought 296,798 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.68M.
Ultragenyx Pharmaceutical made up 0.12% of Candriam SCA's portfolio in Q1 2026, its #176 holding.
Candriam SCA first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 43 quarters since.
Candriam SCA's Ultragenyx Pharmaceutical position peaked at $39.6M in Q3 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.